摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(furan-2-yl)-1H-1,2,4-triazol

中文名称
——
中文别名
——
英文名称
3-(furan-2-yl)-1H-1,2,4-triazol
英文别名
3-(2-Furyl)-1H-1,2,4-triazole;5-(furan-2-yl)-1H-1,2,4-triazole
3-(furan-2-yl)-1H-1,2,4-triazol化学式
CAS
——
化学式
C6H5N3O
mdl
MFCD20502733
分子量
135.125
InChiKey
DRECSUVFISSLIO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3-(furan-2-yl)-1H-1,2,4-triazol 、 在 potassium carbonate 作用下, 以 为溶剂, 以43 %的产率得到(4-((3-(furan-2-yl)-1H-1,2,4-triazol-1-yl)sulfonyl)phenyl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone
    参考文献:
    名称:
    [EN] SULFONYL-TRIAZOLE COMPOUNDS USEFUL AS LIGANDS AND INHIBITORS OF PROSTAGLANDIN REDUCTASE 2
    [FR] COMPOSÉS SULFONYL-TRIAZOLE UTILES EN TANT QUE LIGANDS ET INHIBITEURS DE LA PROSTAGLANDINE RÉDUCTASE 2
    摘要:
    Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. Exemplary compounds can form covalent adducts with reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, to form modified proteins and/or to alter the biological activity of the proteins. Pharmaceutical compositions comprising the compounds and methods of inhibiting prostaglandin reductase 2 (PTGR2) are also described. In addition, methods are described for screening proteins to identify druggable amino acid residues, e.g., druggable tyrosine and/or lysine residues.
    公开号:
    WO2022221451A2
点击查看最新优质反应信息

文献信息

  • Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    申请人:Edwards Louise
    公开号:US20050272779A1
    公开(公告)日:2005-12-08
    The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    本发明涉及公式I的新化合物,包含该化合物的药物配方,以及利用该化合物预防和/或治疗mGluR5受体介导的疾病的用途。
  • Compounds
    申请人:Arora Jalaj
    公开号:US20060122397A1
    公开(公告)日:2006-06-08
    The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    本发明涉及化合物I的新化合物,其制备过程和其中制备的新中间体,含有该化合物的制药配方以及在治疗中使用该化合物的用途。
  • ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
    申请人:Edwards Louise
    公开号:US20080045571A1
    公开(公告)日:2008-02-21
    The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    本发明涉及公式I的新化合物,包括含有该化合物的制药配方,以及该化合物在预防和/或治疗mGluR5受体介导的疾病中的使用。
  • COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE
    申请人:Vicker Nigel
    公开号:US20110112151A1
    公开(公告)日:2011-05-12
    There is provided a compound of formula R 1 —CO—X—Y—Z—R 2 wherein X and Z are each optional groups that are, independently, saturated or unsaturated carbon chains having a length of 1 to 3 carbons; Y is SO, S, SO 2 , CH═CH, CH 2 CH 2 or O; R 1 is wherein denotes the point of attachment; R 2 is a heteroaryl group comprising an optionally substituted 5 or 6 membered ring, which ring contains only carbon and at least one nitrogen, or contains only carbon, and at least two nitrogens and at least one sulfur; and wherein (i) when R 1 is and —CO—X—Y—Z— is CO—CH 2 —SO, CO—CH 2 —S, or CO—CH 2 —SO 2 , R 2 is other than and; (ii) when R 1 is and —CO—X—Y—Z— is —CO—CH 2 —O—, R 2 is other than
    提供了一个化合物的公式R1—CO—X—Y—Z—R2,其中X和Z是可选的基团,它们分别是具有1至3个碳原子的饱和或不饱和碳链;Y是SO、S、SO2、CH═CH、CH2CH2或O;R1是其中的连接点;R2是一个杂环基团,包括一个可选取代的5或6元环,该环仅包含碳和至少一个氮,或仅包含碳、至少两个氮和至少一个硫;其中(i)当R1是且—CO—X—Y—Z—为CO—CH2—SO、CO—CH2—S或CO—CH2—SO2时,R2不是和;(ii)当R1是且—CO—X—Y—Z—为—CO—CH2—O—时,R2不是。
  • 7-Oxo-4-thia-1-azabicyclo(3.2.0)hept-2-ene derivatives
    申请人:HOECHST UK LIMITED
    公开号:EP0127847A1
    公开(公告)日:1984-12-12
    A process for the preparation of a compound of the general formula I is described according to which a compound of the general formula IIb is reacted with a compound of formula III in which L represents a leaving group, generally carrying out the reaction in the presence of a base. R' represents an alkylene, alkenylene or alkynylene group, having from 1 to 4 carbon atoms, and R2 represents a heterocyclic group having a five-membered or 6-membered ring with 1 to 4 heteroatoms, selected from oxygen sulfur and nitrogen, and being linked to the adjacent sulphur atom via a ring carbon atom.
    通式 I 化合物的制备工艺 的制备方法,根据该方法,通式 IIb 的化合物 与通式 III 的化合物反应 其中 L 代表离去基团,通常在碱存在下进行反应。 R' 代表具有 1 至 4 个碳原子的亚烷基、亚烯基或亚炔基,以及 R2 代表杂环基团,具有 1 至 4 个杂质原子的五元环或六元环,这些杂质原子可选 自氧、硫和氮,并通过环上的碳原子与相邻的硫原子相连。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺